Concomitant Toxicokinetics: Techniques for and Interpretation of Exposure Data Obtained During the Conduct of Toxicology Studies

Abstract

Toxicokinetic analyses have become a routine component of preclinical toxicology studies with pharmaceutical candidates. Evaluation of plasma and/or tissue samples from animals used in toxicology studies (or concurrent satellite groups) provides information on dose proportionality, the potential for dose accumulation, and the sex and species differences in distribution and elimination. Toxicokinetic information is used by toxicologists, toxicology management, clinicians, institutional review boards, and regulatory agencies to ensure that exposure has occurred in animal species to a sufficient extent to minimize the potential risk of toxicities in humans. The requirements for descriptive toxicokinetics change depending on the stage of development of new drug candidates. Early in development, documentation of exposure in 1 species and sex of laboratory animal might be enough to justify preliminary development costs and initiation of product development. Later in development, it becomes necessary to know how new drug candidates are distributed and eliminated following subchronic and chronic administration in multiple species and both sexes. Finally, knowledge of toxicokinetics is used to help establish doses in long-term oncogenicity studies. Scientific, public, and regulatory pressures have recently dictated that the number of animals used in toxicology studies be closely monitored and minimized. Toxicokinetic evaluation of new drug candidates by a staggered sampling design is now routinely performed in our laboratories to maximize information obtained while reducing animal use.

Keywords

Metabolism disposition preclinical pharmacokinetics interspecies

References

Bruins AT (1991). Liquid chromatography-mass spectrometry with ion spray and electrospray interfaces in pharmaceutical and biomedical research . J. Chromatogr. 554: 39-46.

Bruins AT (1993). Electrospray, technique and applications. J. Clin. Phys. 90: 1335-1344.

Chasseaud LF (1993). Role of toxicokinetics in toxicity testing. In: Drug Toxicokinetics. PG Welling and FA de la Iglesia (eds). Marcel Dekker, New York. pp. 105-142.

Food and Drug Administration ( 1994). Toxicokinetics: A guidance on the assessment ofsystemic exposure in toxicity studies. Fed. Reg: 59(40): 9756-9759.

Green MD (1993). Nonclinical considerations: Disposition of drugs . In: Integration of Pharmacokinetics, Pharmacodynamics, and Toxicokinetics in Rational Drug Development, A Yacobi , JP Skelly , VP Shah , and LZ Benet (eds). Plenum Press, New York , pp. 33-38.

Halperin-Walega E. , Yacobi A. , and Batra VK (1993). Toxicokinetic studies design and integrated programs . In: Drug Toxicokinetics, PG Welling and FA de la Iglesia (eds). Marcel Dekker, New York, pp. 85-104.

Koritz GD (1981). Toxicokinetics. In: Safety Evaluation of Drugs and Chemicals, WE Lloyd (ed). Hemisphere Publishing, New York, pp. 14-16.

Peck CC ( 1993). Rationale for the effective use of pharmacokinetics and pharmacodynamics in early drug development. In: Integration of Pharmacokinetics, Pharmacodynamics, and Toxicokinetics in Rational Drug Development, A Yacobi , JP Skelly , VP Shah , and LZ Benet (eds). Plenum Press, New York, pp. 1-6.

Wright DS (1993). Analytical method considerations for toxicokinetic studies. In: Drug Toxicokinetics, PG Welling and FA de la Iglesia (eds). Marcel Dekker, New York, pp. 1-18.